Cheng Tian-Yi, Li Jia-Xin, Chen Jing-Yi, Chen Pei-Ying, Ma Lin-Rui, Zhang Gui-Lin, Yan Pei-Yu
Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, People's Republic of China.
Chin Med. 2021 Oct 22;16(1):108. doi: 10.1186/s13020-021-00516-0.
Coronary heart disease (CHD) is a common ischaemic heart disease whose pathological mechanism has not been fully elucidated. Single target drugs, such as antiplatelet aggregation, coronary artery dilation and lipid-lowering medicines, can relieve some symptoms clinically but cannot effectively prevent and treat CHD. Accumulating evidence has revealed that alterations in GM composition, diversity, and richness are associated with the risk of CHD. The metabolites of the gut microbiota (GM), including trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs) and bile acids (BAs), affect human physiology by activating numerous signalling pathways. Due to the advantage of multiple components and multiple targets, traditional Chinese medicine (TCM) can intervene in CHD by regulating the composition of the GM, reducing TMAO, increasing SCFAs and other CHD interventions. We have searched PubMed, Web of science, Google Scholar Science Direct, and China National Knowledge Infrastructure (CNKI), with the use of the keywords "gut microbiota, gut flora, traditional Chinese medicine, herbal medicine, coronary heart disease". This review investigated the relationship between GM and CHD, as well as the intervention of TCM in CHD and GM, and aims to provide valuable insights for the treatments of CHD by TCM.
冠心病（CHD）是一种常见的缺血性心脏病，其病理机制尚未完全阐明。单靶点药物，如抗血小板聚集、冠状动脉扩张和降脂药物，在临床上可以缓解一些症状，但不能有效防治冠心病。越来越多的证据表明，肠道微生物群（GM）的组成、多样性和丰富度的改变与冠心病风险相关。肠道微生物群的代谢产物，包括氧化三甲胺（TMAO）、短链脂肪酸（SCFAs）和胆汁酸（BAs），通过激活众多信号通路影响人体生理。由于具有多成分、多靶点的优势，中药可以通过调节肠道微生物群的组成、降低TMAO、增加SCFAs等方式干预冠心病。我们使用关键词“肠道微生物群、肠道菌群、中药、草药、冠心病”检索了PubMed、科学网、谷歌学术搜索、科学Direct和中国知网。本综述探讨了肠道微生物群与冠心病之间的关系，以及中药对冠心病和肠道微生物群的干预作用，旨在为中药治疗冠心病提供有价值的见解。
